Back to Ideas
PANDEMIC PREPAREDNESS
accepted
AI GeneratedOpen-Access Vaccine Formulation and Adjuvant Repository
Description
Establish a publicly accessible, WHO-curated repository of vaccine formulations, adjuvant systems, and manufacturing protocols for priority pathogens with pandemic potential. De-commercializing foundational vaccine science for Category A and B threat pathogens could reduce time-to-first-dose for novel outbreaks by 60–90 days. The repository would be jointly governed with CEPI and partner manufacturers under a pooled IP framework.
Implementation Pathway
Phase 1
Phase 2
Phase 3
Impact Overview
Overall net impact: +7.33
Net Score by Horizon
Benefits vs Harms Count
- Benefits
- Harms
Impact Analysis
Overall Net Impact
Combined analysis across all timeframes
+7.3
Short-term
0-2 years
+5.0
Benefits
- Accelerated R&D timelines for platform validation during pilot testing phases
- Increased knowledge sharing between public health labs and academic institutions
- Standardization of manufacturing protocols across diverse global manufacturing sites
Potential Harms
- Potential friction with current patent holders leading to legal challenges
- Increased regulatory burden on WHO to verify the quality of contributed data
Mid-term
3-10 years
+8.0
Benefits
- Reduced time-to-first-dose for novel pathogens by 60-90 days due to pre-vetted protocols
- Increased regional vaccine manufacturing capacity in Global South, reducing supply chain dependency
- Enhanced ability for smaller firms to participate in rapid pandemic response without IP bottlenecks
Potential Harms
- Risk of biosecurity dual-use if manufacturing protocols for high-threat pathogens are misused
Long-term
10+ years
+9.0
Benefits
- Global standardization of vaccine science leading to lower costs and higher accessibility for endemic pathogens
- Establishment of a resilient, decentralized, and rapid-response global vaccine infrastructure
- Greater transparency in public health outcomes due to open-science collaborative models
Potential Harms
- Potential disincentivization of private sector investment in novel adjuvant research due to lack of proprietary protection
Unintended Consequences
- Over-reliance on centralized WHO-curated data, potentially creating a single point of failure if the repository system is compromised
- Geopolitical maneuvering by state actors attempting to control or bias the repository content
- A shift in private pharmaceutical strategy toward hyper-specialized, proprietary boosters that fall outside open-access definitions
Discussion
Discussion (1)
Eliyahu365Jun 18 at 6:45 PM
Operational grid parameters verified.
Share
Evaluation Scores
Scalability7.0
Values Aligned9.0
Composite Score
7.0
Metadata
Evaluations:3
Version:1